Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-27 | Dr. Bronstein has served as a member of our board of directors since 2010 and from 2010 to 2011 served as Chief Executive Officer of Aldeyra, then known as Neuron Systems. Since January 2014, Dr. Bronstein has been the Chief Medical Officer of Stealth BioTherapeutics, Inc. Dr. Bronstein serves on the board of directors of a privately held life science company and is a member of the Advisory Committee of the Daedalus Fund for Innovation at Weill Cornell Medical College. In addition, Dr. Bronstein has served as an Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College since November 2013. Previously he served as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 25 years in entrepreneurial roles in life science companies and venture capital firms. Dr. Bronstein has founded or held senior management positions at several venture-backed life science firms, including BioSurface Technology, Inc., a regenerative medicine company; Peptimmune, Inc., an immunotherapeutics company (a spinout from Harvard and MIT); and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma. He has also served as a founder and senior vice president of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. Dr. Bronstein received his M.D. and M.B.A. from Boston University. |
| 2016-04-25 | Dr. Bronstein received his M.D. and M.B.A. from Boston University. Dr. Bronstein’s extensive knowledge of our business and history, experience as a board member of biotechnology companies and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies contributed to our conclusion that he should serve as a director of our company. |
| 2017-04-24 | Dr. Bronstein is a board-certified pathologist and dermatopathologist, with over 20 publications. He received his M.D. and M.B.A. from Boston University. |
| 2018-04-25 | Dr. Bronstein is Executive Vice President, Clinical Development at Aclaris Therapeutics, Inc. Previously he was an active advisor and consultant to life science companies. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 28 years in entrepreneurial and management roles in life science companies and venture capital firms. |
| 2019-04-22 | Dr. Bronstein received his M.D. and M.B.A. from Boston University. |
| 2020-04-27 | Dr. Bronstein received his M.D. and M.B.A. from Boston University. |
| 2021-04-14 | Dr. Bronstein is an independent consultant providing advisory services to companies in the life sciences industry. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 29 years in entrepreneurial and management roles in life science companies and venture capital firms. |
Data sourced from SEC filings. Last updated: 2026-03-05